Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) will report its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss results.
Investors can join by phone (domestic: (800) 715-9871; international: (646) 307-1963; access code 1880547) or via a live and archived webcast in the company's Investor Relations website at https://investors.ceribell.com/.
Positive
- None.
Negative
- None.
News Market Reaction – CBLL
In the Apr 21 session, CBLL declined 0.90%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings date notice | Neutral | -1.1% | Scheduled Q4 and full-year 2025 earnings release and conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For prior earnings date news, CBLL saw a modest negative reaction of -1.06% on average.
Over the last several months, Ceribell combined rapid revenue growth with ongoing investment and regulatory milestones. Q4 2025 revenue was $24.8M and full-year 2025 revenue reached $89.1M, with gross margins of 87% in Q4 and 88% for the year. Operating expenses rose to $136.7M, driving a net loss of $53.4M, though the company ended 2025 with $159.3M in cash and securities. The new Q1 2026 earnings-date announcement follows this February 2026 earnings release pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
